HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: M200482-JLR200v1 44/5/943    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Telford, D. E. Articles by Huff, M. W. Search for Related Content PubMed PubMed Citation Articles by Telford, D. E. Articles by Huff, M. W. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol. 44, 943-952, May 2003
Copyright © 2003 by Lipid Research, Inc.

Inhibition of both the apical sodium-dependent bile acid transporter and HMG-CoA reductase markedly enhances the clearance of LDL apoB

Dawn E. Telford^*, Jane Y. Edwards^*, Sara M. Lipson^*, Brian Sutherland^*, P. Hugh R. Barrett^,, John R. Burnett^,**, Elaine S. Krul, Bradley T. Keller and Murray W. Huff^1,*

^* Robarts Research Institute and Departments of Medicine and Biochemistry, University of Western Ontario, London, Ontario, Canada
Departments of Medicine, University of Western Australia, Perth, Australia
Pathology, University of Western Australia, Perth, Australia
^** Department of Core Clinical Pathology and Biochemistry, Division of Laboratory Medicine, Royal Perth Hospital, Perth, Australia
Western Australian Institute for Medical Research, Perth, Australia
Cardiovascular and Metabolic Diseases Discovery Research, Pharmacia Corporation, St. Louis, MO 63167

¹ To whom correspondence should be addressed. e-mail: mhuff{at}uwo.ca

Discovery of the ileal apical sodium-dependent bile acid transporter (ASBT) permitted development of specific inhibitors of bile acid reabsorption, potentially a new class of cholesterol-lowering agents. In the present study, we tested the hypothesis that combining the novel ASBT inhibitor, SC-435, with the HMG-CoA reductase inhibitor, atorvastatin, would potentiate reductions in LDL cholesterol (LDL-C) and LDL apolipoprotein B (apoB). ApoB kinetic studies were performed in miniature pigs fed a typical human diet and treated with the combination of SC-435 (5 mg/kg/day) plus atorvastatin (3 mg/kg/day) (SC-435+A) or a placebo. SC-435+A decreased plasma total cholesterol by 23% and LDL-C by 40%. Multicompartmental analysis (SAAM II) demonstrated that LDL apoB significantly decreased by 35% due primarily to a 45% increase in the LDL apoB fractional catabolic rate (FCR). SC-435+A significantly decreased hepatic concentrations of free cholesterol and cholesteryl ester, and increased hepatic LDL receptor mRNA consequent to increased cholesterol 7-hydroxylase expression and activity. In comparison, SC-435 (10 mg/kg/day) monotherapy decreased LDL apoB by 10% due entirely to an 18% increase in LDL apoB FCR, whereas atorvastatin monotherapy (3 mg/kg/day) decreased LDL apoB by 30% due primarily to a 22% reduction in LDL apoB production.

We conclude that SC-435+A potentiates the reduction of LDL-C and LDL apoB due to complementary mechanisms of action.

Abbreviations: ASBT, apical sodium-dependent bile acid transporter; FCR, fractional catabolic rate; FXR, farnesoid X receptor; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; LRH-1, liver receptor homolog-1; SHP, short heterodimer partner; SREBP, sterol regulatory element binding protein

Supplementary key words bile acid reabsorption • atorvastatin • kinetics • cholesterol 7-hydroxylase • LDL receptor

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				D. E. Telford, B. G. Sutherland, J. Y. Edwards, J. D. Andrews, P. H. R. Barrett, and M. W. Huff The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin J. Lipid Res., March 1, 2007; 48(3): 699 - 708. [Abstract] [Full Text] [PDF]

				N. Hussainzada, A. Banerjee, and P. W. Swaan Transmembrane Domain VII of the Human Apical Sodium-Dependent Bile Acid Transporter ASBT (SLC10A2) Lines the Substrate Translocation Pathway Mol. Pharmacol., November 1, 2006; 70(5): 1565 - 1574. [Abstract] [Full Text] [PDF]

				C Thomas, J-F Landrier, D Gaillard, J Grober, M-C Monnot, A Athias, and P Besnard Cholesterol dependent downregulation of mouse and human apical sodium dependent bile acid transporter (ASBT) gene expression: molecular mechanism and physiological consequences Gut, September 1, 2006; 55(9): 1321 - 1331. [Abstract] [Full Text] [PDF]

				P Hruz, C Zimmermann, H Gutmann, L Degen, U Beuers, L Terracciano, J Drewe, and C Beglinger Adaptive regulation of the ileal apical sodium dependent bile acid transporter (ASBT) in patients with obstructive cholestasis Gut, March 1, 2006; 55(3): 395 - 402. [Abstract] [Full Text] [PDF]

				D. E. Telford, S. M. Lipson, P. H. R. Barrett, B. G. Sutherland, J. Y. Edwards, J. D. Aebi, H. Dehmlow, O. H. Morand, and M. W. Huff A Novel Inhibitor of Oxidosqualene:Lanosterol Cyclase Inhibits Very Low-Density Lipoprotein Apolipoprotein B100 (ApoB100) Production and Enhances Low-Density Lipoprotein ApoB100 Catabolism Through Marked Reduction in Hepatic Cholesterol Content Arterioscler. Thromb. Vasc. Biol., December 1, 2005; 25(12): 2608 - 2614. [Abstract] [Full Text] [PDF]

				W. A. Alrefai, Z. Sarwar, S. Tyagi, S. Saksena, P. K. Dudeja, and R. K. Gill Cholesterol modulates human intestinal sodium-dependent bile acid transporter Am J Physiol Gastrointest Liver Physiol, May 1, 2005; 288(5): G978 - G985. [Abstract] [Full Text] [PDF]

				A F Hofmann Inappropriate ileal conservation of bile acids in cholestatic liver disease: homeostasis gone awry Gut, September 1, 2003; 52(9): 1239 - 1241. [Full Text]